1. Clinical Overview
Timolol (0.5% w/v) is a non-selective beta-adrenergic receptor blocking agent (beta-blocker) formulated as an ophthalmic solution. It is a cornerstone therapy in the management of open-angle glaucoma and ocular hypertension in the Indian market, primarily by reducing elevated as well as normal intraocular pressure (IOP). It is a first-line agent due to its potent IOP-lowering efficacy, established safety profile, and cost-effectiveness.
| Onset | Duration | Bioavailability |
|---|---|---|
| Ocular hypotensive effect begins within 30 minutes after topical administration. | Peak effect occurs at 1 to 2 hours. A significant reduction in IOP persists for at least 24 hours with a single dose, supporting once or twice-daily dosing. | Systemic bioavailability following topical ocular administration is low but significant (approximately 80% of an administered dose is systemically absorbed via nasolacrimal drainage). |
2. Mechanism of Action
Timolol reduces intraocular pressure (IOP) primarily by decreasing the production of aqueous humor by the ciliary body. It has little to no effect on the outflow facility (conventional uveoscleral outflow). The reduction in aqueous humor formation is mediated through blockade of beta-1 and beta-2 adrenergic receptors in the ciliary processes.
3. Indications & Uses
- Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma
- Ocular hypertension
4. Dosage & Administration
Adult Dosage: One drop of 0.5% solution in the affected eye(s) twice daily. In some patients, the IOP may be adequately controlled with one drop once daily (e.g., in the morning).
Administration: Wash hands before use. Tilt head back, pull lower eyelid down to form a pouch. Instill one drop. Close eyes gently for 1-2 minutes. Apply gentle pressure with a finger to the lacrimal sac (inner corner of the eye) for at least 1 minute to minimize systemic absorption. Wait at least 5-10 minutes before instilling any other topical ophthalmic medication. Do not touch dropper tip to eye or any surface.
5. Side Effects
Common side effects may include:
- Ocular: Transient burning or stinging on instillation, conjunctival hyperemia (redness), superficial punctate keratitis, dry eyes, blurred vision
- Systemic (due to absorption): Bradycardia, hypotension, bronchospasm (in susceptible individuals), headache, dizziness, fatigue
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Beta-Blockers (Oral/Systemic) | Additive systemic beta-blockade leading to severe bradycardia, heart block, heart failure. | Major |
| Calcium Channel Blockers (e.g., Verapamil, Diltiazem) | Potentiates negative inotropic and chronotropic effects; risk of hypotension, bradycardia, and heart failure. | Major |
| Digoxin | Additive effects on AV conduction; increased risk of bradycardia. | Moderate |
| Insulin, Oral Hypoglycemics | Timolol may mask tachycardia (a warning sign) of hypoglycemia and may impair glucose recovery. May also cause hypertension. | Moderate |
| Catecholamine-depleting drugs (e.g., Reserpine) | Additive hypotensive and bradycardic effects; may produce vertigo, syncope. | Major |
| Adrenergic Agonists (e.g., Epinephrine for glaucoma) | Initial hypertensive episode followed by bradycardia. Paradoxical decrease in heart rate. | Moderate |
| Quinidine, CYP2D6 Inhibitors | May inhibit timolol metabolism, increasing systemic levels and risk of adverse effects. | Moderate |
7. Patient Counselling
- DO wash hands before use.
- DO apply nasolacrimal occlusion (pressing finger on inner corner of eye) for 1 minute after instillation to reduce systemic side effects.
- DO wait at least 5-10 minutes before using other eye drops.
- DO NOT touch the dropper tip to your eye, fingers, or any surface.
- DO NOT wear contact lenses while using this medication if the formulation contains benzalkonium chloride (common preservative). Remove lenses before use and wait at least 15 minutes before reinsertion.
- DO NOT stop using this medication suddenly without consulting your doctor, even if you feel well.
8. Toxicology & Storage
Overdose: Ocular Overdose: Excessive instillation may lead to increased systemic absorption and corresponding systemic toxicity. Systemic Overdose: Bradycardia, hypotension, bronchospasm, acute cardiac failure, hypoglycemia, seizures, and coma.
Storage: Store at controlled room temperature (15°C to 25°C). Protect from light. Do not freeze. Keep the bottle tightly closed when not in use. Keep out of reach and sight of children. Discard the bottle 28 days after first opening to prevent contamination. Do not use if the solution changes color or becomes cloudy.